$APRE News
Last published 2d ago
- 2d agoAPREGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - APREA THERAPEUTICS INCEarnings Call TranscriptsSo welcome everyone to this next session. My name is Paul Jang. I'm one of the biotech analysts with Guggenheim. And I'm very pleased to welcome our next presenting company, Aprea Therapeutics. And with us today is Oren
- 2d agoAPREGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - APREA THERAPEUTICS INCEarnings Call TranscriptsSo welcome everyone to this next session. My name is Paul Jang. I'm one of the biotech analysts with Guggenheim. And I'm very pleased to welcome our next presenting company, Aprea Therapeutics. And with us today is Oren
- 6d agoAPREAprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireDOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
- 6d agoAPREAprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireDOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision...
- 1w agoAPREAprea Therapeutics, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
- 1w agoAPREAprea Therapeutics Announces Third Quarter 2026 Financial ResultsGlobeNewswireUpdated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026APR-1051 Phase 1 clinical trial
- 3w agoAPREAprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision OncologyGlobeNewswireDOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
- 2mo agoAPREAprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireDOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
- 2mo agoAPREAprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology ProgramsGlobeNewswireDOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and
- 3mo agoAPREAprea Therapeutics Announces Second Quarter 2026 Financial ResultsGlobeNewswireEnrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and
- 3mo agoLPCNAPREACETLipocine Appoints Michael J. Grissinger to Board of DirectorsPR NewswireLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...
- 3mo agoAPREAprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026GlobeNewswireNext clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
- 4mo agoONNVFAZNAPREBOLD+1Next-Generation DNA Repair Therapies Open New Frontiers in OncologyGlobeNewswireAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which
- 5mo agoAPREAprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid TumorsGlobeNewswirePresentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typesManageable tolerability confirmed across cohortsPatient expansion
- 6mo agoAPREAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswireOversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose
- 6mo agoAPRECatalYm Appoints Christian S. Schade as Chairman of the Board of DirectorsBusiness WireCatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma
- 6mo agoAPREAprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual MeetingGlobeNewswireDOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of
- 7mo agoAPREFrazier Life Sciences Appoints Christian Schade as Senior AdvisorBusiness WireFrazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Christian Schade as Senior Advisor. Chris will join FLS' Boston office and work closely
- 7mo agoAPREAprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementGlobeNewswireDOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of
- 7mo agoAPREAprea Therapeutics Announces Oversubscribed $30 Million Private PlacementGlobeNewswireFinancing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea
- 7mo agoAPREAprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 TrialGlobeNewswireConfirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitorEmerging clinical proof of
- 8mo agoAPREAprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateGlobeNewswireEarly clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team strengthened with
- 8mo agoAPREAprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 TrialGlobeNewswireTumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose levelPatient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A mutation, supporting
- 8mo agoAPREAprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireDOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit
- 9mo agoAPREAprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline GrowthGlobeNewswireNew patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051
- 9mo agoAPREAprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical AdvisorGlobeNewswireDOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit
- 9mo agoAPREAprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First ScanGlobeNewswireApproximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response (uPR) that was observed in the first scan has been achieved at
- 9mo agoAPREAprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswireDOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific
- 10mo agoAPREAprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026GlobeNewswireDOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses
- 11mo agoAPREAprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswireFinancing from new and existing healthcare focused investors The proceeds are expected to extend the Company's cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that
- 12mo agoAPREAprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical UpdateGlobeNewswireAPR-1051 (WEE1 kinase inhibitor): In ongoing Phase 1 ACESOT-1051dose-escalation trial, 3 out of 4 patients at Dose Level 6 (100 mg once daily) achieved stable disease, per RECIST v1.1, in heavily pretreated
- 1y agoAPREAprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051GlobeNewswire3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors
- 1y agoAPREAprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination TherapiesGlobeNewswireATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 monotherapy enrollment paused with strategic focus on high-value combinationCompany is
- 1y agoAPREAprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireDOYLESTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific
- 1y agoAPREAprea Therapeutics to Present at H.C. Wainwright Global Investment ConferenceGlobeNewswireDOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific
- 1y agoAPREAprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical UpdateGlobeNewswireEarly evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051 $16.5
- 1y agoAPREAprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer CenterGlobeNewswirePreclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early
- 1y agoAPREAprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical UpdateGlobeNewswireATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in
- 1y agoACETAPREAdicet Bio Reports First Quarter 2025 Financial Results and Provides Business UpdatesBusiness WireTwo programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with
- 1y agoACETAPREAdicet Bio Appoints Michael Grissinger to the Board of DirectorsBusiness Wire--Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company
- 1y agoAPREAprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 TrialGlobeNewswireDOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific
- 1y agoAPREAprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewswireACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected
- 1y agoAPREAprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)GlobeNewswireDOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific
- 1y agoAPREAprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer TherapeuticsGlobeNewswireDOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific
- 1y agoAPREAprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path ForwardGlobeNewswireTwice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially optimizes
- 2y agoAPREAprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswirePreliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities Philippe Pultar, MD engaged as senior medical advisor to support
- 2y agoAPREAprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsGlobeNewswirePhase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S. Preliminary results to date
- 2y agoAPREAprea Therapeutics to Present at Maxim 2024 Healthcare Virtual SummitGlobeNewswireDOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic
- 2y agoAPREAprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsGlobeNewswireDOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic
- 2y agoAPREAprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical DevelopmentGlobeNewswireDOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic